Ikena Oncology, Inc. (IKNA) Financial Statements (2024 and earlier)

Company Profile

Business Address 50 NORTHERN AVE.
BOSTON, MA 02210
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:156,900232,217
Cash and cash equivalents59,919232,217
Short-term investments 97,028 
Other undisclosed cash, cash equivalents, and short-term investments (47) 
Prepaid expense727850
Other current assets964629
Other undisclosed current assets1,4192,820
Total current assets:160,010236,516
Noncurrent Assets
Operating lease, right-of-use asset5,2556,538
Property, plant and equipment3,2052,439
Restricted cash and investments872872
Other undisclosed noncurrent assets2,9171,514
Total noncurrent assets:12,24911,363
TOTAL ASSETS:172,259247,879
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,8555,723
Employee-related liabilities2,809
Accounts payable2,0932,384
Accrued liabilities3,762530
Deferred revenue9,16017,100
Other liabilities11926
Other undisclosed current liabilities6,3694,340
Total current liabilities:21,50327,189
Noncurrent Liabilities
Long-term debt and lease obligation 5,135
Long-term debt, excluding current maturities  
Liabilities, other than long-term debt3,7877,678
Deferred revenue  7,678
Operating lease, liability3,7875,135
Total noncurrent liabilities:3,78712,813
Total liabilities:25,29040,002
Equity
Equity, attributable to parent146,969207,877
Common stock3636
Additional paid in capital361,915353,295
Accumulated other comprehensive loss(763) 
Accumulated deficit(214,219)(145,454)
Other undisclosed equity  
Total equity:146,969207,877
TOTAL LIABILITIES AND EQUITY:172,259247,879

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
Revenues15,61830,985
Gross profit:15,61830,985
Operating expenses(86,522)(65,123)
Operating loss:(70,904)(34,138)
Nonoperating income2,13923
Investment income, nonoperating  
Other nonoperating income2,13923
Loss from continuing operations:(68,765)(34,115)
Loss before gain (loss) on sale of properties:(34,115)
Net loss available to common stockholders, diluted:(68,765)(34,115)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
Net loss:(68,765)(34,115)
Other comprehensive income763 
Other undisclosed comprehensive income  
Comprehensive loss:(68,002)(34,115)
Other undisclosed comprehensive loss, net of tax, attributable to parent(1,526) 
Comprehensive loss, net of tax, attributable to parent:(69,528)(34,115)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: